A pathogenic haplotype, common in Europeans, causes autosomal recessive albinism and uncovers missing heritability in OCA1

Karen Grønskov1, Cathrine Jespersgaard1, Gitte Hoffmann Bruun2, Pernille Harris3, Karen Brøndum-Nielsen1, Brage S. Andersen2 & Thomas Rosenberg4

Oculocutaneous albinism (OCA) is a genetically heterogeneous disorder. Six genes are associated with autosomal recessive OCA (TYR, OCA2, TYRP1, SLC45A2, SLC24A5 and LRMDA), and one gene, GPR143, is associated with X-linked ocular albinism (OA). Molecular genetic analysis provides a genetic diagnosis in approximately 60% of individuals with clinical OA/OCA. A considerably number of the remaining 40% are heterozygous for a causative sequence variation in TYR. To identify missing causative sequence variants in these, we used a NGS based approach, genotyping and segregation analysis. We report two putative pathogenic haplotypes which only differ by two extremely rare SNVs, indicating that the haplotypes have a common derivation. Both haplotypes segregate consistent with an autosomal recessive inheritance pattern and include the allele p.S192Y-p.R402Q. An explanation for the pathogenicity of the haplotypes could be the combination of p.S192Y and p.R402Q. Homozygosity for the pathogenic haplotypes causes a partial albinism phenotype. In our cohort, 15% of affected individuals had a molecular genetic diagnosis involving the pathogenic haplotype. Consequently, the prevalence of albinism seems to be substantially underestimated, and children with unexplained bilateral subnormal vision and/or nystagmus should be analysed clinically and molecularly for albinism.
Results

NGS analysis. An overview of the workflow is depicted in Fig. S1. To search for the missing mutations, the genomic region of TYR was sequenced in 15 individuals with albinism of whom 12 were heterozygous for a mutation in TYR and three were heterozygous for a mutation in both TYR and OCA2 (Fig. S1 box 2; Table S1). Data analysis revealed a rare SNV (rs147546939A/G, c.1185-6208A > G) located in intron 3, of which the minor allele (G) was present in 11 out of the 15 individuals (Fig. S1 box 3). We further genotyped 78 individuals for rs147546939 (Fig. S1 box 4). In total, out of 93 individuals with albinism, 26 were heterozygous and six were homozygous for rs147546939G (38/186 alleles, MAF: 0.2043) (Fig. S1 box 3 and S). This is significantly increased compared to both a control group from the Genome Denmark study1 where rs147546939G was found in five out of 300 alleles (MAF: 0.0167) (P < 0.0001) and in the gnomAD database (version r2.0.2) where rs147546939G is reported in 269 out of 14956 alleles (non-Finnish Europeans, MAF = 0.018) (Tables 1; S1). Noteworthy, rs147546939G is exclusively present in individuals with albinism who are either heterozygous for a TYR variant (21/58 alleles, MAF = 0.362) or mutation negative (17/94 alleles, MAF = 0.1809) (Fig. S1 box 3 and 5). Therefore, rs147546939G is substantially enriched in individuals with albinism and specifically in those with only one identified pathogenic variant in TYR (P < 0.0001). rs147546939G was not found in any of 32 unaffected family members shown to be carriers of a pathogenic TYR variant.

CNV analysis using the NGS data showed no rare deletions or duplications in the region.

Segregation analysis. Six families were analyzed by segregation analysis, and rs147546939G was in trans with a pathogenic TYR variant in all six families (Fig. 1A). Results from the segregation analysis combined with whole genome sequencing (WGS) of nine OCA individuals (six heterozygous and three homozygous for the G allele of rs147546939) (Fig. S1 box 7) showed a common haplotype of 143 SNVs located in chr11:88811249-89057348 (hg19) (Tables 2 and S2). The haplotype included two rare SNVs (frequency below 2%); rs187887338G, located 100 kb upstream from the TYR translation start site, and the already described rs147546939G. A subset of individuals had further two very rare SNVs (rs145409367T and rs529155220C), which probably arose later in evolution thus resulting in two haplotypes only differing for these two SNVs (Fig. 1; Table S2). We will disregard these two SNVs. Two common coding SNVs: rs1042602A p.Ser192Tyr and rs1126809A p.Arg402Gln were the only coding SNVs in the haplotype. Rare or coding SNVs in the haplotype therefore are: rs187887338G, rs1042602A p.Ser192Tyr, rs1126809A p.Arg402Gln, rs1042602A p.Ser192Tyr and rs1126809A p.Arg402Gln; the haplotype is designated: “GYGQ”.

Functional studies of rs147546939. These results indicate that one or more of the variants shared on the haplotypes are pathogenic. Since rs147546939 is located in intron 3 of TYR (c.1185-6208A > G) and deep intron variants are known to be potentially pathogenic, this variant was further investigated. Analysis of the sequence surrounding rs147546939 showed two potential pseudoexons of 25 bp and 104 bp located immediately downstream of the SNP. To investigate if rs147546939G affects splicing and causes inclusion of the pseudoexon, a minigene was constructed. However, due to the large size of intron 3 of TYR (56802 bp) it was not possible to make a construct encompassing the full intron, instead, a construct with 1902 bp of intron 3 either with rs147546939G or rs147546939A, flanked by part of exon 3 and part of exon 4, was analysed in a minigene construct transfected in the TYR expression cell line ARPE-19 (Fig. S1). Neither the minigene with rs147546939G nor that with rs147546939G included the potential pseudoexon (Fig. 2).

Protein modeling. Protein modeling of TYR has previously been proven useful by others8. We therefore carried out 3D structure modeling of TYR with 402Q and with 192Y-402Q. This shows that the R402 is positioned on the surface of the protein in close vicinity of R403, H404, R405, which means that the surface charge here is highly positive. The effect of changing the arginine to a glutamine (R402Q) is illustrated Fig. S2A where here is highly positive. The effect of changing the arginine to a glutamine (R402Q) is illustrated Fig. S2A where.

| SNP        | Chr. Position (chr 11) | Alleles  | MAFa  | MAFb  | OCA cohort | TYR het and no mutation |
|------------|------------------------|----------|-------|-------|------------|------------------------|
| rs187887338| 88811249               | C/G      | 0.01130| 0.0167| NA         | NA                     |
| rs145409367| 88851587               | C/T      | 0.008135| 0.0067| NA         | NA                     |
| rs1042602 (p.Ser192Tyr)| 88911696         | C/A (S/Y) | 0.3640| 0.31  | 0.5783    | 0.7326                |
| rs529135220 | 88978983               | G/C      | 0.0016 | 0.0067| NA         | NA                     |
| rs147546939 | 89011733               | A/G      | 0.01799| 0.0167| 0.2043    | 0.2533                |
| rs1126809 (p.Arg402Gln)| 89017961          | G/A (R/Q) | 0.2725| 0.28  | 0.3604    | 0.4811                |

Table 1. MAFs rs147546939. (a) Non-Finish Europeans (gnomAD database). (b) Danish ancestry (Genome Denmark study).
Discussion
Many studies of OCA and OA have revealed that a substantial number of cases remain genetically unsolved. A considerable number of these are found to be heterozygous for a pathogenic variant in \(\text{TYR}\), and the number is in excess of that explained by carrier frequency. One variant, 402Q has been subject to extensive discussion over the years, and it has been suggested to be pathogenic both on its own as well as when located in cis with 192Y\textsuperscript{7-11}. The frequency of 28% in the gnomAD database (non-Finnish Europeans) and the identification of unaffected individuals compound heterozygous for a pathogenic variant in \(\text{TYR}\) and 402Q has excluded that this variant on its own is pathogenic. The frequency of 402Q in our cohort was increased in the \(\text{TYR}\) heterozygous and no mutation group (\(\text{MAF} = 0.4811\) compared to genome Denmark 0.28) \((P < 0.0013)\). An increased frequency was also observed for 192Y which has a MAF of 0.31 in the genome Denmark group compared to 0.7326 in the \(\text{TYR}\).
heterozygous and no mutation group (P < 0.00001). Thus, even though the frequencies of 402Q and 192Y are increased in individuals with a clinical diagnosis of albinism who are heterozygous for a pathogenic variant in \textit{TYR} or whom have no identified mutation, the frequencies are far too high to be pathogenic. However, a carrier frequency of 1.9% of the 192Y-402Q allele in a population of European ancestry has been reported\(^7\), and even though this frequency also seems high, we suggest that the 192Y-402Q allele is pathogenic (discussed below).

We present a pathogenic haplotype, in which pathogenic variant(s) are expected to be found among the shared variants, which are either rare or coding (GYGQ). The haplotypes segregate according to an autosomal recessive inheritance pattern and furthermore, have not been observed in unaffected carriers of a \textit{TYR} mutation. Since the rare alleles of rs145409367 and rs529155220 are not present in all individuals these probably have arisen later in evolution and it is therefore unlikely that these SNPs are pathogenic. The deep intron variant rs147546939G was investigated by minigene analysis and demonstrated to have no effect. However, the drastic reduction in the \textit{TYR} intron 3 in the minigene construct could affect the result, and we cannot completely exclude this variant as pathogenic. \(\text{rs187887338G}\) is located 100 kb upstream of the \textit{TYR} translation in a region not evolutionarily conserved and not known to possess enhancers. Thus, we have no data that indicate that \(\text{rs187887338G}\) or \(\text{rs147546939G}\) are pathogenic. The two coding variants, 192Y and 402Q have previously been suggested to be pathogenic when located in \textit{cis}\(^7\). The study by Jagirdar \textit{et al.}\(^7\) shows that in human melanocytes with genotype 192Y-402Q the tyrosinase is retained in the endoplasmic reticulum (ER). The 192Y allele has been shown to have 60% of wild type activity\(^6\). It is plausible that the 192Y-402Q allele would result in a substantial amount

| ID  | rs1878 | rs1454 | S192Y | rs5291 | rs1475 | R402Q | \textit{TYR} mutation | Diagnosis |
|-----|--------|--------|--------|--------|--------|--------|---------------------|----------|
| 22  | G/G    | C/C    | A/A (Y/Y) | G/G    | G/G    | A/A (Q/Q) | No mutation | AROA    |
| 96  | G/G    | C/T    | A/A (Y/Y) | G/C    | G/G    | A/A (Q/Q) | No mutation | AROA    |
| 308 | G/G    | C/T    | A/A (Y/Y) | G/C    | G/G    | A/A (Q/Q) | No mutation | AROA    |
| 288 | G/C    | C/C    | C/A (S/Y) | G/G    | A/G    | A/A (Q/Q) | c.1075C > T | OCA    |
| 44  | G/C    | C/T    | C/A (S/Y) | G/C    | A/G    | A/A (Q/Q) | c.228C > G | OCA    |
| 284 | C/G    | C/C    | C/A (S/Y) | G/G    | A/G    | G/A (R/Q) | c.1467dupT | OCA    |
| 112 | C/G    | C/T    | C/A (S/Y) | G/C    | A/G    | G/A (R/Q) | c.1467dupT | OCA    |
| 236 | C/G    | C/T    | A/A (Y/Y) | C/A    | A/G    | G/A (R/Q) | c.915C > A | AROA    |
| 271 | C/C    | C/C    | C/A (S/Y) | G/G    | C/A    | G/G (R/R) | c.915C > A | AROA    |

**Table 2.** WGS of nine individuals. Haplotypes and clinical diagnosis. Y: tyrosine, S: serine, Q: glutamine, R: arginine, OCA: oculocutaneous albinism, AROA: autosomal recessive ocular albinism. \textit{rs1878}: \textit{rs187887338}, \textit{rs1454}: \textit{rs145409367}, S192Y: \textit{rs1042602}, \textit{rs5291}: \textit{rs529135220}, \textit{rs1475}: \textit{rs147546939}, R402Q: \textit{rs1126809}.

**Figure 2.** Minigene analysis of \textit{rs147546939}. (A) The construct used for transfection. The blue boxes are exon sequences of \textit{TYR}; 3: 91 bp of exon 3; 4: 47 bp of exon 4. The green box indicates the position of \textit{rs147546939}, WT: \textit{rs147546939A} and MUT: \textit{rs147546939G}. The orange box indicates the pseudogene. (B) Transfection of constructs in ARPE cells. Both constructs show inclusion of the 79 bp pseudogene located several kb downstream of \textit{rs147546939} in the normal endogenous \textit{TYR}. The identity of the bands was investigated by sequence analysis.
of tyrosinase being retained in the ER due to 402Q, and further, that the tyrosinase released from the ER has only 60% of wild type activity due to 192Y. This could lower the available tyrosinase activity to a level that is pathogenic.

Comparison of individuals with two pathogenic TYR sequence variants with individuals who are compound heterozygous for the haplotype GYGQ and a pathogenic TYR sequence variant, shows a more severe phenotype in the former group (35 of the 37 had a clinical diagnosis of OCA compared to 15 out of 21 in the latter group; the remaining six has a clinical diagnosis of OA or AROA). Furthermore, the six individuals homozygous for GYGQ, are all from the no mutation group (N = 47). Five of the six individuals were clinically diagnosed with AROA, and thus had a mild albinism phenotype (Table 3). Jagirdar et al. found two individuals homozygous for 192Y-402Q who showed hypopigmentation, however no ophthalmological data were available. Thus it seems that homozygosity for GYGQ causes a mild albinism phenotype.

The frequency of 192Y-402Q of 1.9% is comparable to the frequency of rs187887338G (MAF: 0.011) and rs147546939G (MAF: 0.018) in non-Finnish Europeans. This carrier frequency is surprisingly high if homozygosity for GYGQ causes an albinism phenotype. However, mild albinism might go undetected in a lightly pigmented population, as seen by the study of Sjöström et al. of the Swedish population, who found a prevalence of albinism of about 1% using iris translucency and asymmetric VEP as clinical criteria. This is in contrast to a study of children of Mexican origin where a prevalence of 0.3% was found and, interestingly, the GYGQ haplotype is much less frequent in Latino population as indicated by the lower frequency of an as yet undetected mutation linked to the GYGQ haplotype, however, WGS of nine individuals showed no other mutations including CNVs (deletions or duplications).

In future studies, it would be relevant to introduce the 192Y-402Q allele on a different haplotype background than the one described in this study, and measure the tyrosinase activity, however, this is out of scope for this study.

In conclusion, we report a pathogenic haplotype GYGQ in TYR, which may explain 15% of individuals with albinism in our cohort. The haplotype seems to result in a mild phenotype both when in trans to a pathogenic mutation in TYR and when homozygous. Our results indicate that the prevalence of albinism in European descendants is underestimated, and albinism should be considered as a diagnosis in children with subnormal visual acuity and/or otherwise unexplained nystagmus.

### Methods

**Subjects and clinical examinations.** Ninety-three individuals were selected from a cohort of 177 individuals with a clinical diagnosis of albinism (OCA, AROA or OA) (Table S1, Fig. S1). All individuals were of Scandinavian descent. Most individuals were examined at a National, ophthalmological diagnostic and rehabilitation centre and selected on the basis of the presence of either congenital nystagmus or a visual acuity below 0.3 or both. We used semi-quantitative phenotype assessment to classify patients as either OCA or AROA. In brief, the diagnostic criteria for albinism included nystagmus, reduced visual acuity, iris translucency, fundus hypopigmentation, and foveal hypoplasia. Crossed asymmetry of the retino-cortical projections (misrouting) was used as an additional sign if present.

The project was approved by The National Committee on Health Research Ethics (Denmark). The project was performed according to the Declaration of Helsinki and approved by the Regional Ethics Committee. Written informed consent was obtained from all the participants and if under the age of 18 from a parent or legal guardian, before the molecular genetic testing.

**DNA sequence analysis.** Genomic DNA was extracted from peripheral blood using standard protocols. Individuals were subject to molecular genetic analysis either by Sanger sequencing sequentially of the genes TYR, OCA2, TYRP1, SLC45A2, LRMDA and GPR143 or by a NGS panel (TYR, OCA2, TYRP1, SLC45A2, LRMDA, GPR143, AP3B1, BLOC1S3, BLOC1S6, DYNBP1, HPS1, HPS3, HPS4, HPS5, HPS6, LYST, MITF, MLPH, MYO5A, Rab27A, SLC38A8).

Fifteen individuals were selected for targeted NGS analysis of the genomic regions of TYR (chr11:88900000-89031900, hg19). Targeted libraries for NGS were prepared using Haloplex capture technology (Agilent, Santa Clara, CA, USA). The enriched DNA libraries were sequenced using the MiSeq platform (Illumina, San Diego, CA, USA). The reads were processed using the SureCall program (Agilent), for alignment to the human genome (GRCh37/hg19) with Burrows-Wheeler Aligner (BWA-MEM) and variant calling (SNPPET).

---

### Table 3. Haplotypes and clinical diagnosis of six individuals with no previously identified mutations in TYR Y:

| Sample ID | rs1042602 (S192Y) | rs1126809 (R402Q) | rs147546939A > G | rs529135220G > C | Diagnosis |
|-----------|------------------|-----------------|----------------|----------------|-----------|
| 22        | A/A (Y/Y)        | A/A (Q/Q)       | G/G            | G/G            | AROA      |
| 57        | A/A (Y/Y)        | A/A (Q/Q)       | G/G            | NA             | AROA      |
| 70        | A/A (Y/Y)        | A/A (Q/Q)       | G/G            | NA             | AROA      |
| 96        | A/A (Y/Y)        | A/A (Q/Q)       | G/G            | G/C            | AROA      |
| 262       | A/A (Y/Y)        | A/A (Q/Q)       | G/G            | NA             | OCA       |
| 308       | A/A (Y/Y)        | A/A (Q/Q)       | G/G            | G/C            | AROA      |
To improve coverage, nine individuals were further analysed by whole genome sequencing and data analysis of the TYR genomic region (chr1:88811249–89057348). Genomic DNA was fragmented by an ultrasonicator, purified, blunt ended, A tailed, and adaptor ligated. DNA templates with adapters were enriched using PCR and the concentrations of the libraries were determined. The libraries were sequenced on the Illumina HiSeq platform using paired-end reads according to Illumina manufacturer’s instructions (Illumina). The reads were processed following the Genome Analysis Toolkit (GATK) (https://www.broadinstitute.org/gatk/guide/best-practices). The reads were mapped to the human reference genome (GRCh37/hg19) with BWA, duplicate reads removed by Picard tools (https://broadinstitute.github.io/picard/), variants were called by the HaplotypeCaller of GATK 3.7,8,10.

**CNV analysis.** The Copy Number Variants (CNVs) were called using the CNVnator read-depth algorithm. The algorithm divides the genome into non overlapping bins of equal size and uses the count of mapped reads in each bin as the Read-Depth signal. We used standard settings and a bin size of 100 bp.

**Genotyping of rs147546939, rs529135220, rs187887338 and rs145409367.** Analysis of rs147546939, rs529135220 and rs187887338 was performed by PCR analysis followed by Sanger sequencing using BigDye terminator v3.2 and analysis on an ABI3100XL platform. Primers used for PCR were as follows: rs147546939: Rs147546939-FH acc cac tgc tta ctt gcg tct cAG GCC AGA AAA CTT CAC CAA and Rs147546939-RH gag ggg caa aca aca gat ggc TCA ACA TGA TTT ATT GTC CAC; rs529135220: TYR-c1184-17845-FH acc cac tgc tta ctt gcg tct cAG GCC ATT ATG TCA GGC GGA and TYR-c1184-17845-RH gag ggg caa aca aca gat ggc TCA ACA TGG TTC TTT AAT GTC CAC; rs187887338: TYR-s187887338-FH acc cac ttc ctt gcg tct cTC TCG CTC ATA GGT GGG AAC and TYR-s187887338-RH gag ggg caa aca aca gat ggc CCA TGA AAT CTT TGG GCC ACA. Bases in lower case letters were used for sequencing and are not gene specific. Analysis of rs145409367 was performed by PCR using primers TYR-s145409367-FH acc cac tgc tta ctt gcg tct cAG GAT TTT GCA AAG GTG TTT T and TYR-s145409367-RH gag ggg caa aca aca gat ggc TCA ACA TGG TTC TTT AAT GTC CAC; rs147546939-RH gag ggg caa aca aca gat ggc TTT GCC CCA CTG TTT GCT CC, rs187887338: TYR-s187887338-FH acc cac tgc ttc ctt gcg tct cAA CCT CAC CAG CTA ACC and Rs147546939-RH gag ggg caa aca aca gat ggc TTT GCC CCA CTG TTT GCT CC; rs187887338: TYR-s187887338-FH acc cac tgc ttc ctt gcg tct cAA CCT CAC CAG CTA ACC and Rs147546939-RH gag ggg caa aca aca gat ggc TTT GCC CCA CTG TTT GCT CC; rs187887338: TYR-s187887338-RH gag ggg caa aca aca gat ggc TTT GCC CCA CTG TTT GCT CC. Genomic DNA was fragmented by an ultrasonicator (Ipswich, MA, USA) which only cuts the C allele (major allele).

**Minigene analysis.** A wild type and a mutant TYR minigene carrying the rs147546939 mutation was constructed and cloned into pCDNA3.1 by Genescript. The minigene contains TYR exon 3 (91 bp), 1902 bp of intron 3 and exon 4 (47 bp). Due to its large size, intron 3 was size-reduced. The minigenes were transfected in duplicates into ARPE-19 cells, which are known to express TYR. RNA was isolated and used as template for cDNA synthesis. The splicing of TYR intron 3 was examined by PCR using primers TYR1S AAC TTA AGC TTG GTA CCT TGC ACA TC and TYR2AS GCC TTC GGA GCC ACT GCT C and subsequently analyzed by agarose gel electrophoresis. The splicing of the TYR minigene was quantified using the frame fragmenter (Advanced Analytical AATI).

**Protein modeling.** We modelled the three-dimensional structure of the human tyrosinase protein to predict the effect of the S192Y and the R402Q mutations on protein structure/function. The human tyrosinase related protein 1 (TYRP1) (PDB entry 5mQ8_A)35, which has a sequence identity with human tyrosinase of 44.37% was chosen as the best template for a homology model using an automatic run of SWISS-MODEL36. The resulting structure was investigated using Pymol17.

**Statistics.** Fisher’s exact test, two tailed, was performed to test for significance.

**References**

1. Gronskov, K., Ek, J. & Brondum-Nielsen, K. Oculocutaneous albinism. *Orphanet journal of rare diseases* **2**, 43 (2007).
2. Montoloui, L. et al. Increasing the complexity: new genes and new types of albinism. *Pigment cell & melanoma research* **27**, 11–18 (2014).
3. Maretyt, L. et al. Sequencing and de novo assembly of 150 genomes from denmark as a population reference. *Nature* **548**, 87 (2017).
4. Mannermaa, E. et al. Filter-cultured arpe-19 cells as outer blood-retinal barrier model. *European Journal of Pharmaceutical Sciences* **40**, 289–296 (2010).
5. Bala, K. & Purohit, R. Mutational analysis of tyr gene and its structural consequences in oca1a. *Gene* **513**, 184–195 (2013).
6. Chaki, M. et al. Molecular and functional studies of tyrosinase variants among indian oculocutaneous albinism type 1 patients. The *Journal of investigative dermatology* **131**, 260–262 (2011).
7. Jagirdar, K. et al. Molecular analysis of common polymorphisms within the human tyrosinase locus and genetic association with pigmentation traits. *Pigment cell & melanoma research* **27**, 552–564 (2014).
8. Norman, C. S. et al. Identification of a functionally significant tri-allelic genotype in the tyrosinase gene (tyr) causing hypomorphic oculocutaneous albinism (oca1b). *Scientific reports* **7**, 4415 (2017).
9. Toyofuku, K. et al. Oculocutaneous albinism types 1 and 3 are er retention diseases: mutation of tyrosinase or tyrp1 can affect the processing of both mutant and wild-type proteins. *The FASEB journal* **15**, 2149–2161 (2001).
10. Tripathi, R. K., Giebel, L. B., Strunk, K. M. & Spritz, R. A. A polymorphism of the human tyrosinase gene is associated with temperature-sensitive enzymatic activity. *Gene expression* **1**, 103–110 (1991).
11. Lasseau, E. et al. Molecular characterization of a series of 990 index patients with albinism. *Pigment cell & melanoma research* (2018).
12. Sjöström, A., Kraemer, M., Ohlsson, J. & Villarreal, G. Subnormal visual acuity syndromes (svas): albinism in swedish 12–13-year-old children. *Documenta ophthalmologica* **103**, 35–46 (2001).
13. Sjöström, A. et al. Subnormal visual acuity (svas) and albinism in mexican 12–13-year-old children. *Documenta ophthalmologica* **108**, 9–15 (2004).
14. Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. Cnvnator: an approach to discover, genotype, and characterize typical and atypical cnvs from family and population genome sequencing. *Genome research* **21**, 974–984 (2011).
15. Lai, X., Wichers, H. J., Solés-Lopez, M. & Dijkstra, B. N. Structure of human tyrosinase related protein 1 reveals a binuclear zinc active site important for melanogenesis. *Angewandte Chemie International Edition* **56**, 9812–9815 (2017).
16. Waterhouse, A. et al. Swiss-model: homology modelling of protein structures and complexes. *Nucleic acids research* (2018).
17. Schrödinger, LLC. The PyMOL molecular graphics system, version 1.8 (2015).
Acknowledgements
We would like to thank the patients and their families who participated in this study. We thank Pia Skovgaard for technical assistance. This work were funded by Fight for sight Denmark and The Danish Eye Research Foundation.

Author Contributions
K.G., T.R., K.B.N. and B.S. conceived the experiments, T.R. carried out clinical investigation of the patients and collected samples, K.G., C.J. and G.H.B. conducted the experiments, P.H. performed the protein modeling, K.G., T.R., K.B.N. and B.S. analyzed the results. K.G. drafted the manuscript. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-37272-5.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019